These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 17671656)

  • 21. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
    Brandt L; Skeiky YA; Alderson MR; Lobet Y; Dalemans W; Turner OC; Basaraba RJ; Izzo AA; Lasco TM; Chapman PL; Reed SG; Orme IM
    Infect Immun; 2004 Nov; 72(11):6622-32. PubMed ID: 15501795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines.
    Romano M; Aryan E; Korf H; Bruffaerts N; Franken CL; Ottenhoff TH; Huygen K
    Microbes Infect; 2012 Jan; 14(1):86-95. PubMed ID: 21920450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.
    Triccas JA; Shklovskaya E; Spratt J; Ryan AA; Palendira U; Fazekas de St Groth B; Britton WJ
    Infect Immun; 2007 Nov; 75(11):5368-75. PubMed ID: 17724075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein LpqS deficient M. tuberculosis mutant is attenuated for virulence in vivo and shows protective efficacy better than BCG in guinea pigs.
    Sakthi S; Palaniyandi K; Gupta UD; Gupta P; Narayanan S
    Vaccine; 2016 Feb; 34(6):735-43. PubMed ID: 26768127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
    Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B
    Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The SecA2 pathway of Mycobacterium tuberculosis exports effectors that work in concert to arrest phagosome and autophagosome maturation.
    Zulauf KE; Sullivan JT; Braunstein M
    PLoS Pathog; 2018 Apr; 14(4):e1007011. PubMed ID: 29709019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses.
    Afonso-Barroso A; Clark SO; Williams A; Rosa GT; Nóbrega C; Silva-Gomes S; Vale-Costa S; Ummels R; Stoker N; Movahedzadeh F; van der Ley P; Sloots A; Cot M; Appelmelk BJ; Puzo G; Nigou J; Geurtsen J; Appelberg R
    Cell Microbiol; 2013 Apr; 15(4):660-74. PubMed ID: 23121245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycobacterium tuberculosis Mce3E suppresses host innate immune responses by targeting ERK1/2 signaling.
    Li J; Chai QY; Zhang Y; Li BX; Wang J; Qiu XB; Liu CH
    J Immunol; 2015 Apr; 194(8):3756-67. PubMed ID: 25780035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene.
    Berthet FX; Lagranderie M; Gounon P; Laurent-Winter C; Ensergueix D; Chavarot P; Thouron F; Maranghi E; Pelicic V; Portnoï D; Marchal G; Gicquel B
    Science; 1998 Oct; 282(5389):759-62. PubMed ID: 9784137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCG Vaccination Induces Robust CD4+ T Cell Responses to Mycobacterium tuberculosis Complex-Specific Lipopeptides in Guinea Pigs.
    Kaufmann E; Spohr C; Battenfeld S; De Paepe D; Holzhauser T; Balks E; Homolka S; Reiling N; Gilleron M; Bastian M
    J Immunol; 2016 Mar; 196(6):2723-32. PubMed ID: 26889044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs.
    Martin C; Williams A; Hernandez-Pando R; Cardona PJ; Gormley E; Bordat Y; Soto CY; Clark SO; Hatch GJ; Aguilar D; Ausina V; Gicquel B
    Vaccine; 2006 Apr; 24(17):3408-19. PubMed ID: 16564606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
    Tang C; Yamada H; Shibata K; Maeda N; Yoshida S; Wajjwalku W; Ohara N; Yamada T; Kinoshita T; Yoshikai Y
    J Infect Dis; 2008 May; 197(9):1263-74. PubMed ID: 18422438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of phagosomes infected with Mycobacterium tuberculosis as a vaccine candidate against tuberculosis.
    Sharma A; Parihar P; Sharma J
    Indian J Exp Biol; 2014 Nov; 52(11):1090-7. PubMed ID: 25434104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
    Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice.
    Li W; Deng G; Li M; Zeng J; Zhao L; Liu X; Wang Y
    Mol Immunol; 2014 Nov; 62(1):86-95. PubMed ID: 24980867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine.
    Pinto R; Saunders BM; Camacho LR; Britton WJ; Gicquel B; Triccas JA
    J Infect Dis; 2004 Jan; 189(1):105-12. PubMed ID: 14702160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.
    Sereinig S; Stukova M; Zabolotnyh N; Ferko B; Kittel C; Romanova J; Vinogradova T; Katinger H; Kiselev O; Egorov A
    Clin Vaccine Immunol; 2006 Aug; 13(8):898-904. PubMed ID: 16893990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.